On Tuesday, Biogen Inc (NASDAQ: BIIB) was 3.57% up from the session before settling in for the closing price of $125.59. A 52-week range for BIIB has been $110.04 – $238.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -18.66%. When this article was written, the company’s average yearly earnings per share was at -9.99%. With a float of $146.25 million, this company’s outstanding shares have now reached $146.50 million.
Let’s determine the extent of company efficiency that accounts for 7605 employees. In terms of profitability, gross margin is 75.58%, operating margin of 23.17%, and the pretax margin is 17.85%.
Biogen Inc (BIIB) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Biogen Inc stocks. The insider ownership of Biogen Inc is 0.19%, while institutional ownership is 89.93%. The most recent insider transaction that took place on May 19 ’25, was worth 480,508. In this transaction Head of Development of this company sold 3,806 shares at a rate of $126.25, taking the stock ownership to the 5,427 shares. Before that another transaction happened on May 19 ’25, when Company’s Officer proposed sale 3,806 for $126.25, making the entire transaction worth $480,508.
Biogen Inc (BIIB) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -9.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.76% during the next five years compared to -18.66% drop over the previous five years of trading.
Biogen Inc (NASDAQ: BIIB) Trading Performance Indicators
You can see what Biogen Inc (BIIB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.03. Likewise, its price to free cash flow for the trailing twelve months is 7.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.13, a number that is poised to hit 4.07 in the next quarter and is forecasted to reach 15.43 in one year’s time.
Technical Analysis of Biogen Inc (BIIB)
Looking closely at Biogen Inc (NASDAQ: BIIB), its last 5-days average volume was 1.23 million, which is a drop from its year-to-date volume of 1.61 million. As of the previous 9 days, the stock’s Stochastic %D was 41.84%.
During the past 100 days, Biogen Inc’s (BIIB) raw stochastic average was set at 42.57%, which indicates a significant decrease from 51.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.94% in the past 14 days, which was lower than the 34.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $125.72, while its 200-day Moving Average is $148.89. However, in the short run, Biogen Inc’s stock first resistance to watch stands at $134.90. Second resistance stands at $139.73. The third major resistance level sits at $144.72. If the price goes on to break the first support level at $125.09, it is likely to go to the next support level at $120.10. Should the price break the second support level, the third support level stands at $115.27.
Biogen Inc (NASDAQ: BIIB) Key Stats
There are 146,528K outstanding shares of the company, which has a market capitalization of 19.06 billion. As of now, sales total 9,676 M while income totals 1,632 M. Its latest quarter income was 2,431 M while its last quarter net income were 240,500 K.
